摘要
研究目的
通过观察B转化生长因子(TGF-β1)、β转化生长因子Ⅱ型受体(TβRⅡ)及增殖细胞核抗原(PCNA)在泪腺上皮性肿瘤中的表达情况,并分别分析TGF-β1与TβRⅡ、PCNA的相关性,进而探讨TGF-β1信号通路在泪腺上皮性肿瘤发生与发展中的作用,及TGF-β1在泪腺上皮性肿瘤细胞增殖中的生物学作用,为将TGF-β1信号通路引入泪腺上皮性肿瘤的诊断、治疗及预后判断提供客观依据。
研究方法
1.收集2003年11月至2008年11月期间在天津市眼科医院诊断为泪腺上皮性肿瘤患者的临床病理资料。
2.应用免疫组织化学法检测TGF-β1、TβRⅡ及PCNA在泪腺上皮性肿瘤中的表达情况。
3.应用SPSS13.0统计学软件对数据进行分析。
研究结果
1 TGF-β1蛋白主要表达于细胞胞质内,偶见于胞核,其表达与患者年龄、性别、肿瘤大小、发病时间无关。TGF-β1蛋白的平均光密度(AOD)值在正常泪腺组,泪腺良性上皮性肿瘤组及恶性上皮性肿瘤组分别为0.0192±0.0062,0.0857±0.0484,0.2414±0.0751,三组间两两比较有统计学差异(P<0.05)。TGF-β1蛋白的AOD值在良性上皮性肿瘤初发组及复发组中分别为0.0626±0.0213,0.2370±0.0778,两组间比较有统计学差异(P<0.05)；其在恶性肿瘤初发组与复发组中分别为0.2390±0.0743,0.2502±0.0713,两组间比较无统计学差异(P>0.05)。
2 TβRⅡ蛋白主要表达于细胞胞质内,其表达与患者年龄、性别、肿瘤大小、发病时间无关。TβRⅡ蛋白在正常泪腺组,泪腺良性上皮性肿瘤组及恶性上皮性肿瘤组间均有表达,其AOD值分别为0.2548±0.0292,0.2498±0.0285,0.2497±0.0314,三组间两两比较无明显统计学差异(P>0.05); TβRⅡ蛋白的AOD值在泪腺良性上皮性肿瘤初发组及复发组中分别为0.2504±0.0301,0.2501±0.0334,两组间比较无统计学差异(P>0.05)；其在恶性肿瘤初发组与复发组中分别为0.2489±0.0279,0.2481±0.0241,两组间比较无统计学差异(P>0.05)。
3 PCNA蛋白主要表达于细胞胞核,其表达与患者年龄、性别、肿瘤大小、发病时间无关。PCNA蛋白的平均光密度(AOD)值在正常泪腺组,泪腺良性上皮性肿瘤组及恶性上皮性肿瘤组分别为0.133±0.0213,0.17±0.0234,0.2445±0.0323,三组间两两比较有统计学差异(P<0.05)。PCNA蛋白的AOD值在泪腺良性上皮性肿瘤初发组及复发组中分别为0.1499±0.0468,0.2431±0.0314,两组间比较有统计学差异(P<0.05)；其在恶性上皮性肿瘤初发组与复发组中分别为0.2344±0.0306,0.2647±0.0261,两组间比较有统计学差异(P<0.05)。
4.泪腺上皮性肿瘤中TGF-β1与PCNA蛋白表达呈正相关(P<0.05),TGF-β1与TβRⅡ表达无明显相关性(P>0.05)。
结论
1. TGF-β1参与了泪腺上皮性肿瘤的发生与发展,可预测良性上皮性肿瘤的复发性。
2.在泪腺上皮性肿瘤中TβRⅡ无明显表达缺失,其可能不是导致TGF-β1失去抑制细胞增殖作用的重要因素。
3. PCNA可以反映泪腺上皮性肿瘤细胞的增殖活性及肿瘤的恶性程度并评价泪腺上皮性肿瘤的预后及生物活性,为临床早期干预提供理论依据。
4. TGF-β1随着肿瘤恶性程度的增强,其抑制细胞增殖的作用减弱,可能失去了抑制细胞增殖、调控细胞分化的生物学功能,并且其高表达可能促进了肿瘤细胞的增殖。
Objective
This study is to investigate the expressions of TGF-β1, TβRⅡand PCNA in lacrimal gland epithelial tumors,it evaluates the possible role of TGF-β1 signaling pathway in the occurrence and development of lacrimal gland tumor. Simultaneously, it clarifies whether TGF-β1 plays role in cell proliferation by analysis the relevance of TGF-β1 and PCNA.That will be benfit to the diagnosis and treatment,and to evaluate the prognosis of lacrimal gland tumor as a theoretical basis.
Methods
1. Collect the linical and pathological information of patients diagnosed as lacrimal gland epithelial tumors from November 2003 to November 2008 in Tianjin Eye Hospital.
2. Immunohistochemical staining was used to detect the expression of TGF-β1, TβRⅡand PCNA in lacrimal gland epithelial tumors.
3. The data was analyzed by SPSS 13.0 statistical software.
Results
1. TGF-β1, TβRⅡprotein were mainly localized in the cytoplasm, and PCNA protein was localized in cell nuclei,their expressions have nothing to do with ages,sexs, tumor size and course of disease.
2. The AOD values of TGF-β1 protein respectively were 0.0192±0.0062,0.0857±0.0484,0.2414±0.0751 in the normal group,benign group and malignant goup,significant difference among them(P<0.05); The AOD values of TGF-β1 protein respectively were 0.0626±0.0213,0.2370±0.0778 in no recurrence group of the benign epithelial tumors and recurrence group,significant difference between them(P<0.05). The AOD values of TGF-β1 protein respectively were 0.2390±0.0743,0.2502±0.0713 in no recurrence group of the malignant epithelial tumors and recurrence group,no difference between them(P>0.05).
3. The AOD values of TβRⅡprotein respectively were 0.2548±0.0292,0.2498±0.0285,0.2497±0.0314 in the normal group,benign group and malignant goup, there were no significant differences among them (P> 0.05); The AOD values of TβRⅡprotein respectively were 0.2504±0.0301,0.2501±0.0334 in no recurrence group of the benign epithelial tumors and recurrence group,no difference between them (P> 0.05). The AOD values of TβRⅡprotein respectively were 0.2489±0.0279,0.2481±0.0241 in no recurrence group of the malignant epithelial tumors and recurrence group,no difference between them(P>0.05).
4. The AOD values of PCNA protein respectively were 0.133±0.0213,0.17±0.0234,0.2445±0.0323 in the normal group,benign group and malignant goup,significant difference among them(P<0.05); The AOD values of PCNA protein respectively were 0.1499±0.0468,0.2431±0.0314 in no recurrence group of the benign epithelial tumors and recurrence group,significant difference between them(P <0.05). The AOD values of PCNA protein respectively were 0.2344±0.0306,0.2647±0.0261 in no recurrence group of the malignant epithelial tumors and recurrence group, significant difference between them(P<0.05).
5. The positive correlation was showed between protein expression levels of TGF-β1 and PCNA in lacrimal gland tumors (P<0.05); protein expression levels of TGF-β1 and TβRⅡwere no significant correlation (P> 0.05).
Conclusion
1. TGF-β1 participates in the occurrence and development of lacrimal gland tumor,and possibily play a important role in reccurence of benign epithelial tumors.
2. TPRⅡprotein possibily was no loss in lacrimal gland tumors, and it had no relationship with TPRⅡprotein that TGF-β1 can not inhibit the cell proliferation.
3. PCNA can reflect cell proliferation of lacrimal gland tumor, and evaluate the clinical biological behavior of lacrimal gland tumor.
4. TGF-β1 can't play a biological role of inhibiting the cell proliferation with the increasing of the degree of tumor malignancy and the high expression of TGF-β1 may promote tumor cell to proliferate.
引文
[1]Warner MA, Weber AL, and Jakobiec FA. Benign and malignant tumors of the orbital cavity including the lacrimal gland[J]. Neuroimaging Clin N Am,1996, 6(1):123-42.
[2]Shields JA, Shields CL, and Scartozzi R. Survey of 1264 patients with orbital tumors and simulating lesions:The 2002 Montgomery Lecture, part 1[J]. Ophthalmology,2004,111(5):997-1008.
[3]Pokutta SWeis WI. Structure of the dimerization and beta-catenin-binding region of alpha-catenin[J]. Mol Cell,2000,5(3):533-43.
[4]Uthoff SM, Eichenberger MR, McAuliffe TL, et al. Wingless-type frizzled protein receptor signaling and its putative role in human colon cancer[J]. Mol Carcinog,2001,31(1):56-62.
[5]Ilyas M, Tomlinson IP, Rowan A, et al. Beta-catenin mutations in cell lines established from human colorectal cancers[J]. Proc Natl Acad Sci U S A,1997, 94(19):10330-4.
[6]Park C, Kim WS, Choi Y, et al. Effects of transforming growth factor beta (TGF-beta) receptor on lung carcinogenesis[J]. Lung Cancer,2002,38(2): 143-7.
[7]Saji H, Nakamura H, Awut I, et al. Significance of expression of TGF-beta in pulmonary metastasis in non-small cell lung cancer tissues [J]. Ann Thorac Cardiovasc Surg,2003,9(5):295-300.
[8]Paik SY, Park YN, Kim H, et al. Expression of transforming growth factor-betal and transforming growth factor-beta receptors in hepatocellular carcinoma and dysplastic nodules[J]. Mod Pathol,2003,16(1):86-96.
[9]Shattuck-Brandt RLDuBois RN. The molecular basis of colorectal carcinogenesis[J]. Curr Opin Gastroenterol,1999,15(1):3-8.
[10]Li F, Cao Y, Townsend CM, Jr., et al. TGF-beta signaling in colon cancer cells[J]. World J Surg,2005,29(3):306-11.
[11]Djaborkhel R, Tvrdik D, Eckschlager T, et al. Cyclin A down-regulation in TGFbetal-arrested follicular lymphoma cells[J]. Exp Cell Res,2000,261(1): 250-9.
[12]Shariat SF, Kim JH, Andrews B, et al. Preoperative plasma levels of transforming growth factor beta(1) strongly predict clinical outcome in patients with bladder carcinoma[J]. Cancer,2001,92(12):2985-92.
[13]Uchida D, Kawamata H, Omotehara F, et al. Over-expression of TSC-22 (TGF-beta stimulated clone-22) markedly enhances 5-fluorouracil-induced apoptosis in a human salivary gland cancer cell line[J]. Lab Invest,2000,80(6): 955-63.
[14]Kawamata H, Nakashiro K, Uchida D, et al. Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell[J]. Br J Cancer,1998,77(1):71-8.
[15]al ZLe. Histological typing of the eye and its adexa.International histological classification of tumors[J]. WHO, Geneva1980, No.24.
[16]Weis E, Rootman J, Joly TJ, et al. Epithelial lacrimal gland tumors:pathologic classification and current understanding[J]. Arch Ophthalmol,2009,127(8): 1016-28.
[17]Wright GERJE. Pleomorphic adenoma of the lacrimal gland[J]. Br J Ophthalmol.,1992 July,76(7):395-400.
[18]Aaltonen V, Koivunen J, Laato M, et al. Heterogeneity of cellular proliferation within transitional cell carcinoma:correlation of protein kinase C alpha/betaI expression and activity[J]. J Histochem Cytochem,2006,54(7):795-806.
[19]Derynck R, Akhurst RJ, and Balmain A. TGF-beta signaling in tumor suppression and cancer progression[J]. Nat Genet,2001,29(2):117-29.
[20]Huang SS, Leal SM, Chen CL, et al. Cellular growth inhibition by TGF-betal involves IRS proteins[J]. FEBS Lett,2004,565(1-3):117-21.
[21]Chi XZ, Yang JO, Lee KY, et al. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor{beta}-activated SMAD[J]. Mol Cell Biol,2005, 25(18):8097-107.
[22]Kim SG JH, Kim TY, Lee JW, Kim NK, Hong SH, Bang YJ. Transforming growth factor-beta 1 induces apoptosis through Fas ligand-independent activation of the Fas death pathway in human gastric SNU-620 carcinoma cells.[J]. Mol Biol Cell.,2004 15(2):420-34.
[23]Florenes VA, Bhattacharya N, Bani MR, et al. TGF-beta mediated Gl arrest in a human melanoma cell line lacking p15INK4B:evidence for cooperation between p21Cip1/WAF1 and p27Kip1[J]. Oncogene,1996,13(11):2447-57.
[24]Arteaga CL, Dugger TC, and Hurd SD. The multifunctional role of transforming growth factor (TGF)-beta s on mammary epithelial cell biology[J]. Breast Cancer Res Treat,1996,38(1):49-56.
[25]Lynch MA, Petrel TA, Song H, et al. Responsiveness to transforming growth factor-beta (TGF-beta)-mediated growth inhibition is a function of membrane-bound TGF-beta type Ⅱ receptor in human breast cancer cells[J]. Gene Expr,2001,9(4-5):157-71.
[26]Sheen-Chen SM, Chen HS, Sheen CW, et al. Serum levels of transforming growth factor betal in patients with breast cancer[J]. Arch Surg,2001,136(8): 937-40.
[27]Levy LHill CS. Alterations in components of the TGF-beta superfamily signaling pathways in human cancer[J]. Cytokine Growth Factor Rev,2006, 17(1-2):41-58.
[28]Akhurst RJ. TGF-beta antagonists:why suppress a tumor suppressor?[J]. J Clin Invest,2002,109(12):1533-6.
[29]Narayan S, Thangasamy T, and Balusu R. Transforming growth factor-beta receptor signaling in cancer[J]. Front Biosci,2005,10:1135-45.
[30]Roberts ABWakefield LM. The two faces of transforming growth factor beta in carcinogenesis[J].Proc Natl Acad Sci U S A,2003,100(15):8621-3.
[31]Xiong B, Yuan HY, Hu MB, et al. Transforming growth factor-betal in invasion and metastasis in colorectal cancer[J]. World J Gastroenterol,2002,8(4): 674-8.
[32]Dumont NArteaga CL. Targeting the TGF beta signaling network in human neoplasia[J]. Cancer Cell,2003,3(6):531-6.
[33]Ye SC, Foster JM, Li W, et al. Contextual effects of transforming growth factor beta on the tumorigenicity of human colon carcinoma cells[J]. Cancer Res, 1999,59(18):4725-31.
[34]Coban S, Yuksel 0, Kockar MC, et al. The significance of serum transforming growth factor beta 1 in detecting of gastric and colon cancers[J]. Hepatogastroenterology,2007,54(77):1472-6.
[35]Wang KS, Hu ZL, Li JH, et al. Enhancement of metastatic and invasive capacity of gastric cancer cells by transforming growth factor-betal[J]. Acta Biochim Biophys Sin (Shanghai),2006,38(3):179-86.
[36]Lin Y KS, Obata Y, et al. Serum levels of transforming growth factor betal are significantly correlated with venous invasion in patients with gastriccancer[J]. J Gastroenterol Hepatol,,200621 (2):432-437.
[37]Saltzman BS, Yamamoto JF, Decker R, et al. Association of genetic variation in the transforming growth factor beta-1 gene with serum levels and risk of colorectal neoplasia[J]. Cancer Res,2008,68(4):1236-44.
[38]Harman SM, Metter EJ, Blackman MR, et al. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer[J]. J Clin Endocrinol Metab, 2000,85(11):4258-65.
[39]Lin SJ, Lerch TF, Cook RW, et al. The structural basis of TGF-beta, bone morphogenetic protein, and activin ligand binding[J]. Reproduction,2006, 132(2):179-90.
[40]Jakowlew SB. Transforming growth factor-beta in cancer and metastasis[J]. Cancer Metastasis Rev,2006,25(3):435-57.
[41]Li AG, Lu SL, Han G, et al. Current view of the role of transforming growth factor beta 1 in skin carcinogenesis[J]. J Investig Dermatol Symp Proc,2005, 10(2):110-7.
[42]Wrana JL. TGF-beta receptors and signalling mechanisms [J]. Miner Electrolyte Metab,1998,24(2-3):120-30.
[43]Galliher AJ, Neil JR, and Schiemann WP. Role of transforming growth factor-beta in cancer progression[J]. Future Oncol,2006,2(6):743-63.
[44]Bollard CM, Rossig C, Calonge MJ, et al. Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunity[J]. Blood,2002,99(9):3179-87.
[45]Park K, Kim SJ, Bang YJ, et al. Genetic changes in the transforming growth factor beta (TGF-beta) type Ⅱ receptor gene in human gastric cancer cells: correlation with sensitivity to growth inhibition by TGF-beta[J]. Proc Natl Acad Sci U S A,1994,91(19):8772-6.
[46]Hahn SA SM, Hoque AT, Moskaluk CA, da Costa LT, Rozenblum E, Weinstein CL, Fischer A, Yeo CJ, Hruban RH, Kern SE. DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1.[J]. Science.,1996 271(5247): 350-3.
[47]Pepper MS. Transforming growth factor-beta:vasculogenesis, angiogenesis, and vessel wall integrity[J]. Cytokine Growth Factor Rev,1997,8(1):21-43.
[48]Bhowmick NA, Chytil A, Plieth D, et al. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia[J]. Science,2004, 303(5659):848-51.
[49]Poser I, Rothhammer T, Dooley S, et al. Characterization of Sno expression in malignant melanoma[J]. Int J Oncol,2005,26(5):1411-7.
[50]Cappello F, Palma A, Martorana A, et al. Biological aggressiveness evaluation in prostate carcinomas:immunohistochemical analysis of PCNA and p53 in a series of Gleason 6 (3+3) adenocarcinomas[J]. Eur J Histochem,2003,47(2): 129-32.
[51]Grossi F, Loprevite M, Chiaramondia M, et al. Prognostic significance of K-ras, p53, bcl-2, PCNA, CD34 in radically resected non-small cell lung cancers[J]. Eur J Cancer,2003,39(9):1242-50.
[52]Stroescu C, Dragnea A, Ivanov B, et al. Expression of p53, Bcl-2, VEGF, Ki67 and PCNA and prognostic significance in hepatocellular carcinoma[J]. J Gastrointestin Liver Dis,2008,17(4):411-7.
[53]Liu WG, Gu WZ, Zhou YB, et al. The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms'tumour[J]. Eur J Clin Invest,2008,38(12):931-8.
[54]Cvejic D, Savin S, Petrovic I, et al. Galectin-3 and proliferating cell nuclear antigen (PCNA) expression in papillary thyroid carcinoma[J]. Exp Oncol,2005, 27(3):210-4.
[55]Augustynowicz A, Dzieciol J, Barwijuk-Machala M, et al. Assessment of proliferative activity of thyroid Hurthle cell tumors using PCNA, Ki-67 and AgNOR methods[J]. Folia Histochem Cytobiol,2004,42(3):165-8.
[1]Taipale JKeski-Oja J. Growth factors in the extracellular matrix[J]. FASEB J, 1997,11(1):51-9.
[2]Roberts AB. Molecular and cell biology of TGF-beta[J]. Miner Electrolyte Metab,1998,24(2-3):111-9.
[3]Colwell AS, Faudoa R, Krummel TM, et al. Transforming growth factor-beta, Smad, and collagen expression patterns in fetal and adult keratinocytes[J]. Plast Reconstr Surg,2007,119(3):852-7.
[4]Barcellos-Hoff MH. Latency and activation in the control of TGF-beta[J]. J Mammary Gland Biol Neoplasia,1996,1(4):353-63.
[5]Chen WWahl SM. TGF-beta:receptors, signaling pathways and autoimmunity[J]. Curr Dir Autoimmun,2002,5:62-91.
[6]Lin HYMoustakas A. TGF-beta receptors:structure and function[J]. Cell Mol Biol (Noisy-le-grand),1994,40(3):337-49.
[7]Feng XHDerynck R. A kinase subdomain of transforming growth factor-beta (TGF-beta) type I receptor determines the TGF-beta intracellular signaling specificity[J].EMBO J,1997,16(13):3912-23.
[8]Heldin CH, Landstrom M, and Moustakas A. Mechanism of TGF-beta signaling to growth arrest, apoptosis, and epithelial-mesenchymal transition[J]. Curr Opin Cell Biol,2009,21(2):166-76.
[9]张文岚邢,李广生.Smad蛋白家族与TGF-β信号传导[J].深圳中西医结合杂志,2003,13(3)：178-180.
[10]王启伟朴.Smad蛋白信号网络[J].国外医学分子生物学分册,2003,25(4)：206-209.
[11]Stopa M, Benes V, Ansorge W, et al. Genomic locus and promoter region of rat Smad7, an important antagonist of TGFbeta signaling[J]. Mamm Genome, 2000,11(2):169-76.
[12]Poser I, Rothhammer T, Dooley S, et al. Characterization of Sno expression in malignant melanoma[J]. Int J Oncol,2005,26(5):1411-7.
[13]Cho HJ BK, Saika S, Jeong MJ, Yoo J. Snail is required for transforming growth factor-beta-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway.[J]. Biochem Biophys Res Commun.,2007 353((2):):337-43.
[14]Fu H, Hu Z, Wen J, et al. TGF-beta promotes invasion and metastasis of gastric cancer cells by increasing fascin1 expression via ERK and JNK signal pathways[J]. Acta Biochim Biophys Sin (Shanghai),2009,41(8):648-56.
[15]Kretzschmar M, Doody J, Timokhina I, et al. A mechanism of repression of TGFbeta/Smad signaling by oncogenic Ras[J]. Genes Dev,1999,13(7): 804-16.
[16]Berger DH, O'Mahony CA, Sheng H, et al. Intestinal transformation results in transforming growth factor-beta-dependent alteration in tumor cell-cell matrix interactions[J]. Surgery,2003,133(5):568-79.
[17]Schnabl B, Kweon YO, Frederick JP, et al. The role of Smad3 in mediating mouse hepatic stellate cell activation[J]. Hepatology,2001,34(1):89-100.
[18]Kirkbride KCBlobe GC. Inhibiting the TGF-beta signalling pathway as a means of cancer immunotherapy[J]. Expert Opin Biol Ther,2003,3(2):251-61.
[19]Brandes ME, Wakefield LM, and Wahl SM. Modulation of monocyte type Ⅰ transforming growth factor-beta receptors by inflammatory stimuli[J]. J Biol Chem,1991,266(29):19697-703.
[20]Gunnlaugsdottir B, Maggadottir SM, and Ludviksson BR. Anti-CD28-induced co-stimulation and TCR avidity regulates the differential effect of TGF-beta1 on CD4+and CD8+naive human T-cells[J]. Int Immunol,2005,17(1):35-44.
[21]Logullo AF, Nonogaki S, Miguel RE, et al. Transforming growth factor beta1 (TGFbeta1) expression in head and neck squamous cell carcinoma patients as related to prognosis[J]. J Oral Pathol Med,2003,32(3):139-45.
[22]Langenskiold M, Holmdahl L, Falk P, et al. Increased TGF-beta 1 protein expression in patients with advanced colorectal cancer[J]. J Surg Oncol,2008, 97(5):409-15.
[23]Li X, Yue ZC, Zhang YY, et al. Elevated serum level and gene polymorphisms of TGF-betal in gastric cancer[J]. J Clin Lab Anal,2008,22(3):164-71.
[24]Kang HG, Chae MH, Park JM, et al. Polymorphisms in TGF-betal gene and the risk of lung cancer[J]. Lung Cancer,2006,52(1):1-7.
[25]Guo F, Jian XC, and Cheng RX. [Expression of TGF beta 1 and TGF beta RI proteins in tissues of salivary adenoid cystic carcinoma][J]. Hunan Yi Ke Da Xue Xue Bao,2002,27(3):229-32.
[26]Stover DG, Bierie B, and Moses HL. A delicate balance:TGF-beta and the tumor microenvironment[J]. J Cell Biochem,2007,101(4):851-61.
[27]Pardali K MA. Actions of TGF-beta as tumor suppressor and pro-metastatic factor in human cancer[J]. Biochim Biophys Acta.,2007,1775((1)):21-62.
[28]Pasche B. Role of transforming growth factor beta in cancer[J]. J Cell Physiol, 2001,186(2):153-68.
[29]王瑾任.转化生长因子β在恶性肿瘤中的研究现状与进展[J].辽宁医学杂志,2004,18(4)：205-207.
[30]Kim HP, Kim BG, Letterio J, et al. Smad-dependent cooperative regulation of interleukin 2 receptor alpha chain gene expression by T cell receptor and transforming growth factor-beta[J]. J Biol Chem,2005,280(40):34042-7.
[31]Lee C, Sintich SM, Mathews EP, et al.Transforming growth factor-beta in benign and malignant prostate[J]. Prostate,1999,39(4):285-90.
[32]Gorelik LFlavell RA. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells[J]. Nat Med, 2001,7(10):1118-22.
[33]Goggins M, Shekher M, Turnacioglu K, et al. Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas[J]. Cancer Res,1998,58(23):5329-32.
[34]Chen T, de Vries EG, Hollema H, et al. Structural alterations of transforming growth factor-beta receptor genes in human cervical carcinoma[J]. Int J Cancer, 1999,82(1):43-51.
[35]Valle L, Serena-Acedo T, Liyanarachchi S,et al. Germline allele-specific expression of TGFBR1 confers an increased risk of colorectal cancer[J]. Science,2008,321(5894):1361-5.
[36]Shattuck-Brandt RLDuBois RN. The molecular basis of colorectal carcinogenesis[J]. Curr Opin Gastroenterol,1999,15(1):3-8.
[37]Li F, Cao Y, Townsend CM, Jr., et al. TGF-beta signaling in colon cancer cells[J]. World J Surg,2005,29(3):306-11.
[38]Hougaard S, Norgaard P, Abrahamsen N, et al. Inactivation of the transforming growth factor beta type Ⅱ receptor in human small cell lung cancer cell lines[J]. Br J Cancer,1999,79(7-8):1005-11.
[39]Komuro A, Yashiro M, Iwata C, et al. Diffuse-type gastric carcinoma: progression, angiogenesis, and transforming growth factor beta signaling[J]. J Natl Cancer Inst,2009,101(8):592-604.
[40]陈学敏李.TGF-β1、TGF-βRⅡ和CDK4在原发性肝细胞肝癌中的表达及其意义[J].中国普通外科杂志,2005,14(2)：146-148.
[41]Muro-Cacho CA, Rosario-Ortiz K, Livingston S, et al. Defective transforming growth factor beta signaling pathway in head and neck squamous cell carcinoma as evidenced by the lack of expression of activated Smad2[J]. Clin Cancer Res,2001,7(6):1618-26.
[42]Reinholz MM, An MW, Johnsen SA, et al. Differential gene expression of TGF beta inducible early gene (TIEG), Smad7, Smad2 and Bard1 in normal and malignant breast tissue[J]. Breast Cancer Res Treat,2004,86(1):75-88.
[43]Yang X, Letterio JJ, Lechleider RJ, et al. Targeted disruption of SMAD3 results in impaired mucosal immunity and diminished T cell responsiveness to TGF-beta[J]. EMBO J,1999,18(5):1280-91.
[44]Ijichi H. [TGF-beta signaling pathway in pancreatic cancer cells][J]. Nippon Rinsho,2004,62(7):1241-8.
[45]Yakicier MC, Irmak MB, Romano A, et al. Smad2 and Smad4 gene mutations in hepatocellular carcinoma[J]. Oncogene,1999,18(34):4879-83.
[46]Leng A, Liu T, He Y, et al. Smad4/Smad7 balance:a role of tumorigenesis in gastric cancer[J]. Exp Mol Pathol,2009,87(1):48-53.
[47]龚家顺,罗和生,周中银.Smad4在大肠癌发生中的作用及意义[J].胃肠病学和肝病学杂志,2005,14(4)：810-819.
[48]Baldus SE, Schwarz E, Lohrey C, et al. Smad4 deficiency in cervical carcinoma cells[J]. Oncogene,2005,24(5):810-9.
[49]Park YN, Chae KJ, Oh BK, et al. Expression of Smad7 in hepatocellular carcinoma and dysplastic nodules:resistance mechanism to transforming growth factor-beta[J]. Hepatogastroenterology,2004,51(56):396-400.
[50]Kleeff J, Ishiwata T, Maruyama H, et al. The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer[J]. Oncogene,1999, 18(39):5363-72.
[51]Herbert BS, Sanders BG, and Kline K. N-(4-hydroxyphenyl)retinamide activation of transforming growth factor-beta and induction of apoptosis in human breast cancer cells[J]. Nutr Cancer,1999,34(2):121-32.
[52]El Etreby MF, Liang Y, and Lewis RW. Induction of apoptosis by mifepristone and tamoxifen in human LNCaP prostate cancer cells in culture[J]. Prostate, 2000,43(1):31-42.
[53]Kawajiri H, Yashiro M, Shinto O, et al. A novel transforming growth factor beta receptor kinase inhibitor, A-77, prevents the peritoneal dissemination of scirrhous gastric carcinoma[J]. Clin Cancer Res,2008,14(9):2850-60.
[54]Nam JS, Terabe M, Mamura M, et al. An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments[J]. Cancer Res,2008,68(10):3835-43.
[55]Turco A, Scarpa S, Coppa A, et al. Increased TGFbeta type II receptor expression suppresses the malignant phenotype and induces differentiation of human neuroblastoma cells[J]. Exp Cell Res,2000,255(1):77-85.
[56]崔澄.TGF-β1介导的肿瘤免疫抑制研究及临床意义[J].实用肿瘤杂志,2005,20(5)：457-460.
[57]杨镇洲糜,朱俊东,等.大豆异黄酮对乳腺癌细胞TGF-β表达的影响[J].肿瘤防治研究,2001,28(2)：86.